上海医药(02607) - 2021 Q4 - 年度财报

Product Performance - The company achieved a total of 44 products with over 100 million in industrial sales revenue, including 40 key products and 4 non-key products[2] - The product categories covered include cardiovascular, digestive system, immune metabolism, systemic anti-infection, mental neurology, and anti-tumor[2]